• KOLs
  • White Matter
  • Joanna Marguerite Wardlaw

Joanna Marguerite Wardlaw: Influence Statistics

Joanna Marguerite Wardlaw

Joanna Marguerite Wardlaw

UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom | Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK | ...

Joanna Marguerite Wardlaw: Expert Impact

Concepts for which Joanna Marguerite Wardlaw has direct influence: White matter , Ischemic stroke , Lacunar stroke , Magnetic resonance , Ischaemic stroke , Acute stroke , Acute ischaemic stroke .

Joanna Marguerite Wardlaw: KOL impact

Concepts related to the work of other authors for which for which Joanna Marguerite Wardlaw has influence: Ischemic stroke , White matter , Cognitive impairment , Magnetic resonance , Intravenous thrombolysis , Mechanical thrombectomy , Cerebral microbleeds .

KOL Resume for Joanna Marguerite Wardlaw

Year
2022

UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom

From the BHF Centre for Cardiovascular Science, University of Edinburgh, The Chancellor's Building, 49 Little France Crescent, EH16 4SB, Edinburgh, Scotland (J.K., M.S., G.M., M.J., S.I.S., C.A.C., A.A.S.T., S.D., M.R.D., E.J.R.v.B., D.E.N., M.C.W.); Centre for Heart Lung Innovation, St Paul's Hospital and University of British Columbia, Vancouver, Canada (S.S., J.L.); Laboratory Medicine Program, University Health Network, General Hospital, Toronto, Canada (M.A.S.); Royal Infirmary of Edinburgh, Edinburgh, Scotland (M.D., R.F., A.T., W.W., J.W.); Edinburgh Imaging, Queen's Medical Research Institute, Edinburgh, Scotland (G.M., S.I.S., T.M., E.J.R.v.B., D.E.N., M.C.W.); and Department of Medicine, Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif (P.J.S.).

Centre for Clinical Brain Sciences, University of Edinburgh

2021

Centre for Clinical Brain Sciences, The University of Edinburgh, UK

Geriatric Medicine, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

Prominent publications by Joanna Marguerite Wardlaw

KOL-Index: 24823 . BACKGROUND: The majority of strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred. Successful treatment could mean that the patient is more likely to make a good recovery from their stroke. Thrombolytic drugs however, can also cause serious bleeding in the brain which can ...
Known for Data Trials | Acute Ischaemic Stroke | Thrombolytic Therapy | 95 Death
KOL-Index: 23358 . BACKGROUND: Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase. METHODS: We did a pre-specified meta-analysis of ...
Known for Stroke Severity | Treatment Delay | Randomised Trials | Individual Patient Data
KOL-Index: 20907 . OBJECTIVES: To evaluate the accuracy of routinely available non-invasive tests (spiral computed tomographic angiography (CTA), time of flight magnetic resonance angiography (MRA), and colour Doppler ultrasound (DUS)), individually and together, compared with intra-arterial digital subtraction angiography (DSA) in patients with symptomatic tight carotid stenosis; and to assess the effect of ...
Known for Cta Mra | Carotid Endarterectomy | Sensitivity Specificity | Digital Subtraction
KOL-Index: 20743 . BACKGROUND: Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator ...
Known for Ischaemic Stroke | 80 Years | Thrombolytic Therapy | Treatment Rtpa
KOL-Index: 20128 . BACKGROUND: The cause of cerebral small vessel disease is not fully understood, yet it is important, accounting for about 25% of all strokes. It also increases the risk of having another stroke and contributes to about 40% of dementias. Various processes have been implicated, including microatheroma, endothelial dysfunction and inflammation. A previous review investigated endothelial ...
Known for Lacunar Stroke | Endothelial Dysfunction | Blood Markers | Tnf Α
KOL-Index: 18776 . BACKGROUND: Cerebral microbleeds are a neuroimaging biomarker of stroke risk. A crucial clinical question is whether cerebral microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom the rate of future intracranial haemorrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs. We therefore aimed to ...
Known for Ischaemic Stroke | Cerebral Microbleeds | Intracranial Haemorrhage | Pooled Analysis
KOL-Index: 18136 . BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to 6 h from stroke onset. METHODS: In this international, multicentre, randomised, open-treatment trial, patients ...
Known for Recombinant Tissue | Stroke Trial | 6 Months | Rtpa Control
KOL-Index: 17824 . BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used ...
Known for Antiplatelet Therapy | Intracerebral Haemorrhage | Participants Median | Label Trial
KOL-Index: 17523 . BACKGROUND: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for ...
Known for Acute Ischaemic Stroke | Blood Pressure | Intravenous Alteplase | Functional Status
KOL-Index: 17395 . BACKGROUND: Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral ...
Known for Antiplatelet Therapy | Intracerebral Haemorrhage | Stroke Risk | Small Vessel
KOL-Index: 17118 . BACKGROUND: The majority of strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and could improve recovery after stroke. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator ...
Known for Ischaemic Stroke | Patients Trials | Thrombolytic Therapy | Treatment Hours
KOL-Index: 17028 . BACKGROUND AND PURPOSE: In patients with acute ischemic stroke, a high blood pressure or a highly variable blood pressure is a common reason for withholding thrombolytic treatment, but guidelines recommend a conservative approach to active blood pressure lowering in this setting. We have performed exploratory analyses to study the clinical effects of blood pressure and early blood ...
Known for Blood Pressure | 24 Hours | Ischemic Stroke | Thrombolytic Treatment
KOL-Index: 16567 . BACKGROUND: General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies compared with patients treated without GA. We assessed functional outcome in ischaemic stroke patients with large vessel anterior circulation occlusion undergoing endovascular thrombectomy under GA, versus thrombectomy not under GA (with or without ...
Known for Endovascular Thrombectomy | Functional Outcome | General Anaesthesia | Ischaemic Stroke
KOL-Index: 16307 . BACKGROUND: Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to determine the proportional and absolute effects of alteplase on the risks of intracerebral haemorrhage, mortality, and functional impairment in different types ...
Known for Intracerebral Haemorrhage | Acute Ischaemic Stroke | Patients Alteplase | Individual Patient Data
KOL-Index: 15212 . RATIONALE: As the population of the world ages, age-related cognitive decline is becoming an ever-increasing problem. However, the changes in brain structure that accompany normal aging, and the role they play in cognitive decline, remain to be fully elucidated. AIMS: This study aims to characterize changes in brain structure in old age, and to investigate relationships between brain aging ...
Known for Lothian Birth Cohort | Brain Aging | Vascular Disease | Cognitive Decline

Key People For White Matter

Top KOLs in the world
#1
Stephen M Smith
uk biobank functional connectivity multiple sclerosis
#2
Mark Jenkinson
multiple sclerosis white matter uk biobank
#3
Paul McMahan Matthews
multiple sclerosis magnetic resonance uk biobank
#4
Heidi Johansen‐Berg
white matter multiple sclerosis physical activity
#5
Timothy Edward John Behrens
prefrontal cortex white matter human connectome project
#6
†Susumu Mori
white matter diffusion tensor imaging magnetic resonance

UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom | Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK | Centre for Clinical Brain Sciences, UK Dementia Research Institute, Univers